Comparison of Feto-Maternal Outcome in Azithromycin Versus Erythromycin in Management of PPROM; A Randomized Controlled Trial
Abstract
Objective: To compare the efficacy and safety of azithromycin with erythromycin on the duration of latency period till delivery in patients with PPROM.
Methodology: A randomized control trial study was carried out at Department of Obs and Gynae, Federal Government Polyclinic Hospital from May 2023 to May 2024. A total of 210 patients participated in the study equally distributed through lottery method in Group A (n=105) and Group B (n=105). Group A were given Azithromycin 1g once a day till 10 days meanwhile Group B were given Erythromycin 250mg 6 hourly in a day to evaluate the feto-maternal outcome of the drug. Chi Square test was used to compare the neonatal outcomes (birth weight, APGAR scores, NICU admission rates, RDS incidence, and neonatal survival) and maternal outcome (chorioamnionitis and mode of delivery (SVD vs. LSCS) between groups. P-Value ≤0.05 was considered statistically significant
Results: The study observed a significantly longer latency period in group A (5.86±5.50) while group B present (2.94±2.43) with p-value (0.0001). Similarly, Group A showed improved outcome in neonates like high APGAR score, reduced NICU admissions and chorioamnionitis rate in the patients.
Conclusion: Azithromycin 1g single-dose therapy is superior to Erythromycin in improving fetomaternal outcomes due to its enhanced convenience and maternal compliance. Its use should be considered a more effective alternative in clinical scenarios requiring antibiotic therapy during pregnancy, emphasizing better maternal and neonatal well-being.
Copyright (c) 2025 Journal of The Society of Obstetricians and Gynaecologists of Pakistan

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.